Inventages Venture Capital Investment
Inventages is a corporate venture capital arm of Nestlé, founded in 2000 and based in Nassau, Bahamas. The firm specializes in early-stage investments, focusing primarily on life sciences, nutrition, and wellness sectors. It seeks to invest in a range of companies, from seed to late-stage ventures, and provides mezzanine and bridge financing. Inventages targets investments in healthcare, pharmaceuticals, cosmeceuticals, and diagnostic medical devices, emphasizing innovative technologies and services. In the pharmaceutical sector, it invests in small molecules, proteins, antibodies, and vaccines, among others. Its diagnostic investments include genetic materials and biomarkers, while its focus on enabling technologies encompasses novel packaging and supply chain management. Additionally, Inventages supports companies in medical foods, nutraceuticals, and health management, aiming to drive advancements in nutrition and functional food.
Top Sectors
Top Regions
https://crunchbase.com/organization/***
https://linkedin.com/company/***
Past deals in Dietary Supplements
MSI Methylation Sciences
Series A in 2011
MSI Methylation Sciences, Inc. is a biotechnology company founded in 2007 and based in West Vancouver, Canada. The company focuses on developing oral and small molecule therapies for the adjunctive treatment of Major Depressive Disorder (MDD). Their primary product, Strada, is an orally administered therapy designed to alleviate the symptoms of depression in patients suffering from this condition. Additionally, MSI Methylation Sciences develops S-Adenosyl Methionine, a prescription drug utilized as a dietary supplement, which leverages the capabilities of ademetionine, a naturally occurring molecule integral to the one-carbon cycle in the body. Through its innovative approaches, the company aims to enhance treatment options for individuals facing MDD.
DiObex
Series B in 2007
DiObex, Inc. operates as a biotechnology company in the United States. The company develops novel products for the treatment of metabolic disorders, including type-one and type-two diabetes, dyslipidemia, obesity, and diabetic nephropathy. Its products include DIO-901, a very low dose glucagon product that is developed for the reduction of nocturnal hypoglycemia in patients with type-one diabetes; and DIO-902, a cortisol synthesis inhibitor that is developed as a therapy for glucose and cholesterol control in patients with type-two diabetes. DiObex, Inc. was founded in 2003 and is based in San Francisco, California.
Technologie BiolActis
Series A in 2006
Technologie BiolActis (BiolActis) is a Canadian biotechnology company incorporated in 1998. Since its foundation, the entrepreneurs were committed to create novel Biologics meeting well identified needs from the Wellness Industries (Functional Nutrition, Dietary Supplements, Cosmeceuticals and Pharmaceuticals).
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.